Prion Early Detection Science accelerates drug innovation. We aim for personalized treatments to eradicate Alzheimer’s & Parkinson’s diseases.
How does Amprion’s Prion Early Detection Science help accelerate drug development for Alzheimer’s disease and Parkinson’s disease?
Our PMCA (also known as RT-QuIC) technology replicates the protein misfolding process, which often takes 10 to 30 years in the brain and reduces it down to a few hours in the laboratory.
As a result, Amprion detects Alzheimer’s disease and Parkinson’s disease decades before the start of any symptoms, providing people with early diagnosis when the damage to the brain is minimal.
Amprion’s ability to identify and monitor the prion biomarkers in Alzheimer’s and Parkinson’s patients empowers us to develop targeted drugs with pharmaceutical companies in treating the specific biomarkers.
Our Prion Detection Science enables drug companies to target recruit the right patients for the right clinical trials, increasing the chances of success in the drug development pathway.
Our goal is to enrich scientific research and development to accelerate treatment innovation to eradicate Alzheimer’s and Parkinson’s diseases.
Ultimately, we aim to provide people with personalized medicine that best matches their biomarker profiles.
GET UPDATES ON TESTING AVAILABILTY,
BRAIN HEALTH INFO AND FOLLOW AMPRION’S PROGRESS.